Although drugs with sedative properties may increase the risk of airway collapse during sleep, their acute effects on the apnea-hypopnea index in older adults are under-reported. We investigated the acute effects of gabapentin (GABA) on sleep breathing in older men without sleep apnea. A double-blind, randomized, placebo-controlled cross-over pilot study using a bedtime dose of gabapentin 300 mg was conducted in eight nonobese older men. Polysomnography measured the effects of the intervention. The apnea-hypopnea index was higher in the gabapentin arm than in the placebo arm (22.4 AE 6.1 versus 12.2 AE 4.3, P ≤ 0.05, d: 0.67), as was the oxygen desaturation index (20.6 AE 5.8 versus 10.8 AE 3.9, P ≤ 0.05, d: 0.68). The number needed to harm was four. A subset analysis demonstrated that differences in sleep respiratory parameters were present only during non-rapid eye movement sleep, as well as only in the supine position. No adverse events were reported. Hence, gabapentin worsened sleep breathing acutely compared with placebo. Long-term clinical trials are warranted to elucidate the clinical relevance of these findings for the safety profile of GABAergic agents.
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IN TROD UCTI ON
Ageing is a risk factor for obstructive sleep apnea (OSA), the prevalence of which ranges from 30 to 80% in older adults (Epstein et al., 2009) . Airway obstruction during sleep results in hypoxaemia, hypercapnia, increased sympathetic activity and sleep fragmentation, leading to excessive daytime sleepiness, impaired cognition, depressive symptoms, nocturia and higher risk of falls. Furthermore, OSA has been associated consistently with the risk of chronic age-related public health issues, such as hypertension, diabetes and cardiovascular diseases (Maeder et al., 2016) .
Recently, Bliwise et al. (2010) suggested that age-related skeletal muscle deterioration is potentially associated with the airway collapsibility during sleep in elderly people. Therefore, the chronic use of medications with musclerelaxing properties might be an additional risk factor for OSA in older adults. However, little evidence regarding the effects of these agents on the development of OSA is available (Seda et al., 2014) .
For instance, gabapentin, a gamma-aminobutyric acid (GABA)-simile agent, is prescribed increasingly to elderly people (Beal et al., 2012; Trenkwalder et al., 2015) . Among the neuromuscular effects derived from GABA activity, skeletal muscle relaxation may increase airway collapsibility (Dolly and Block, 1982) . Although Furey et al. (2014) reported positive findings for gabapentin in the treatment of insomnia, and its off-label use for chronic disorders is observed increasingly (Fukada et al., 2012) , this drug might lead to worsening in polysomnographic (PSG) respiratory parameters. To test this hypothesis, we sought to investigate the acute effects of gabapentin on sleep breathing parameters in older men without a previous OSA diagnosis.
METH ODS
This was a double-blind, randomized, placebo-controlled cross-over pilot study (Fig. 1) . The local institutional review board approved the protocol. Written informed consents were obtained from subjects before enrollment. The trial is registered with ClinicalTrials.gov (NTC02599701).
Community-dwelling non-obese men (≥60 years old) without severe or uncontrolled chronic diseases were included. The exclusion criteria consisted of neuropsychiatric ª 2017 European Sleep Research Society disorders, current alcoholism, current or previous tabagism, nocturia (>2 voids per night), psychoactive drug use, Berlin questionnaire indicating high risk for OSA, other sleep disorders (based on sleep complaints and PSG) and number of apneas-hypopneas per hour (AHI) ≥15 (Appendix S1). Clinical assessments and blood samples were used to exclude uncontrolled conditions, such as hypertension, diabetes, dyslipidaemia, impaired renal function and thyroid disorders. Laboratory-based PSGs were recorded with a digital system device (S7000; Embla Systems, Thornton, CO, USA) during the participant's habitual sleep times. The criteria for scoring sleep followed previous guidelines (Iber et al., 2007) .
The participants were assigned to one of the intervention arms (gabapentin 300 mg or placebo at bedtime) using block randomization of size four. Tablets containing the placebo or gabapentin were prepared and packed in the same fashion. After a 1-week washout, the same procedure was repeated following the cross-over design. Adverse events (AEs) assessments and vital sign measurements were performed before bedtime and after awakening.
A sample-size estimate of eight individuals per intervention in a pair-matching design considered a minimally clinically important AHI increase from the mean for the maximum expected range of the baseline AHI (0 ≤ AHI < 15) to the AHI threshold for moderate OSA diagnosis (AHI = 15). Sleep breathing parameters [AHI and oxygen desaturation index (ODI)] were considered primary endpoints. Other PSG variables were considered secondary endpoints. Subset analyses of the primary endpoints [non-rapid eye movement (REM) or REM sleep and supine or non-supine position] were performed.
Intervention responses were compared by Wilcoxon's signed-rank test. Cohen's d measured effect sizes. Number needed to harm (NNH) was calculated using the American Academy of Sleep Medicine recommendation for continuous positive airway pressure (CPAP) treatment (AHI ≥ 20) (Kushida et al., 2006) . Randomization order effect was assessed by analysis of covariance (ANCOVA). Spearman's correlation assessed the effect of age on the main outcome's response to gabapentin by testing the relationship between age and AHI change from placebo to gabapentin. AEs were classified by severity and judged according to their potential relation to the medication. All comparisons assumed 0.05 as a significance level using two-sided tests. We used SPSS version 20 for the analysis.
RESULTS
Eight community-dwelling non-obese older men without sleep disorders participated in the study. Baseline participant characteristics are described in Table 1 . The AHI was higher in the gabapentin arm than in the placebo arm (22.4 AE 6.1 versus 12.2 AE 4.3, P ≤ 0.05) ( Table 2 ). Effect size for AHI was moderate (d: 0.67), and the NNH was 4. Most of the respiratory events were obstructive. No differences between interventions were found in the sleep time spent in the supine position. ODI was higher in the gabapentin arm (20.6 AE 5.8 versus 10.8 AE 3.9, P ≤ 0.05), with a moderate effect size 
DI SCUSSION
This randomized, double-blind, single-dose, cross-over pilot study indicated that gabapentin increased AHI and ODI acutely in older men without OSA. We believe this is the first report of the negative effects of an anticonvulsant drug on respiratory parameters during sleep. The effect sizes for the primary outcomes were greater than those observed in a trial for flurazepam and a meta-analysis for opioids (Dolly and Block, 1982; Filiatrault et al., 2016) . A smaller effect size was also found in a previous study investigating the effects of antipsychotics on AHI (Rishi et al., 2010) . No previous NNH estimates regarding pharmacological effects in OSA were found for comparisons. Although adverse events were not reported, the study design was unable to provide conclusive results on the long-term effects of this intervention on sleep respiratory measurements and, consequently, on OSArelated symptoms or clinical consequences in older healthy men. A higher magnitude of AHI increase was observed in the participants with a baseline AHI closer to 15, suggesting that effect size might be even higher if participants with OSA were included into the study, although this hypothesis requires further investigation. Moreover, participants two and three had an increase in AHI after receiving placebo. This tendency persisted once these two participants received gabapentin. Similarly, both participants had the highest AHI during REM sleep at baseline (Appendix S2). It is therefore possible to hypothesize that those participants already had a higher risk to develop moderate to severe OSA in comparison to other participants at baseline, which was worsened by the drug. Further investigation may clarify whether a higher AHI during REM sleep is a risk factor for drug-induced OSA worsening, particularly regarding the use of gabapentin. Several mechanisms regulating respiration during sleep may be associated with these findings. As with other psychoactive drugs, gabapentin can affect the breathing pattern during sleep through muscle relaxation, suppression of (Seda et al., 2014) . Increasing gabapentin use for commonly observed conditions in older individuals means that further study is warranted (Minkel and Krystal, 2013) . Only a few small short-term clinical trials have tested the effects of gabapentin on objective sleep parameters. None of them were focused on sleep breathing (Furey et al., 2014; Lo et al., 2010) . Additionally, older adults are under-represented in studies regarding the gabapentin effects during PSG, and OSArelated symptoms are under-reported in this age group.
Moreover, adverse effects occur more frequently as the population ages. Pharmacological interventions are potential mediators of sleep disorders in aged groups. Antipsychotics were associated previously with severe OSA (Rishi et al., 2010) . Our study excluded older men with sleep disorders and a baseline AHI ≥ 15, strengthening the hypothesis that OSA exacerbation may be related to drug prescriptions even in mild OSA. However, our conclusions are limited by the small sample size, by the interindividual variability in the results and by the use of a single-dose intervention.
The chronic use of GABAergic agonists, such as gabapentin, may impact upon OSA development in older adults. Of note, gabapentin is prescribed not only for longer periods but also in higher dosages than the one used in the current study. Furthermore, the pharmacological effects of this drug on the sleep of older adults with different characteristics and with comorbidities have not yet been addressed. As the global population ages, chronic conditions and multidrug prescriptions are increasingly common, leading to concerns about the impact of pharmacological interventions upon sleep disorders. Long-term clinical trials including larger samples aimed at elucidating this concern are warranted. 
